OLSON LAURIE J

SEC source: 0001562180-24-004024 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,738

F1 · kind: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023.

F2 · balance_after: Includes 2,947 restricted stock units.

SEC source: 0001562180-24-003148 · primarydocument.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,124

Underlying: Common Stock · 1,000 shares

Expires 2033-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-003148 · primarydocument.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,238

F1 · kind: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023.

F2 · balance_after: Includes 4,461 restricted stock units.

SEC source: 0001562180-24-003148 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001140361-24-013931 · form4.xml · derivative · entry 5

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,904 shares

Expires 2033-06-19

F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F5 · derivative.exercise_date: These Options originally provided for vesting upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such date.

SEC source: 0001140361-24-013931 · form4.xml · derivative · entry 4

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 5,000 shares

Expires 2032-06-14

F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F4 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001140361-24-013931 · form4.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 8,500 shares

Expires 2031-06-15

F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F4 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001140361-24-013931 · form4.xml · derivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 13,000 shares

Expires 2030-08-11

F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F3 · kind: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F3 · price: Pursuant to the Merger Agreement, outstanding and unexercised options to purchase shares of Common Stock (the "Options"), whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), were cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such Option multiplied by (ii) the excess, if any, of the Merger Consideration over the exercise price per share of Common Stock under such Option.

F4 · derivative.exercise_date: These Options are fully vested.

SEC source: 0001140361-24-013931 · form4.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · kind: On March 18, 2024, Bristol-Myers Squibb Company ("Bristol-Myers") acquired Karuna Therapeutics, Inc. (the "Issuer") pursuant to a certain Agreement and Plan of Merger, dated as of December 22, 2023 (the "Merger Agreement"), by and among the Issuer, Bristol-Myers and Miramar Merger Sub Inc., a wholly owned subsidiary of Bristol-Myers ("Merger Sub"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as a wholly owned subsidiary of Bristol-Myers. At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock, $0.0001 par value per share (the "Common Stock") (other than certain excluded shares of Common Stock) automatically converted into the right to receive $330.00 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding tax.

F2 · kind: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

F2 · shares: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

F2 · price: Represents restricted stock units ("RSUs"), each representing a contingent right to receive one share of Common Stock. Pursuant to the Merger Agreement, each outstanding RSU, whether granted under an Issuer stock plan or otherwise, automatically vested (to the extent not previously vested), was cancelled and entitled the holder to receive a one-time lump sum payment in an amount in cash, without interest and subject to deduction for any required tax withholding, equal to (i) the total number of shares of Common Stock subject to such RSU immediately prior to the effective time of the Merger, multiplied by (ii) the Merger Consideration.

SEC source: 0001562180-24-001341 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 15,238

F1 · kind: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023.

F2 · balance_after: Includes 4,461 restricted stock units.

SEC source: 0001562180-24-000234 · primarydocument.xml · derivative · entry 5

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 11,124

Underlying: Common Stock · 1,000 shares

Expires 2033-01-03

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-24-000234 · primarydocument.xml · derivative · entry 4

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,412

Underlying: Common Stock · 6,412 shares

Expires 2034-01-02

F4 · shares: Represents non-qualified stock option to purchase 6,412 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy.

SEC source: 0001562180-24-000234 · primarydocument.xml · nonDerivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,738

F3 · kind: The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023.

F2 · balance_after: Includes 4,461 restricted stock units.

SEC source: 0001562180-24-000234 · primarydocument.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,738

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · balance_after: Includes 4,461 restricted stock units.

SEC source: 0001562180-24-000234 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,738

F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2024 granted pursuant to the Quanterix Corporation Amended and Restated Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 4,461 restricted stock units.

SEC source: 0001562180-23-007670 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,791

F1 · kind: The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted on August 14, 2023.

F2 · balance_after: Includes 9,597 restricted stock units.

SEC source: 0000950170-23-031696 · ownership.xml · derivative · entry 4

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 13,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

F4 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0000950170-23-031696 · ownership.xml · nonDerivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 990

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.70 to $216.43, inclusive.

SEC source: 0000950170-23-031696 · ownership.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,390

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.70 to $215.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (3) to this Form 4.

SEC source: 0000950170-23-031696 · ownership.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,990

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

SEC source: 0000950170-23-029400 · ownership.xml · derivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,904

Underlying: Common Stock · 1,904 shares

Expires 2033-06-19

F2 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates.

SEC source: 0000950170-23-029400 · ownership.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 990

F1 · shares: Comprised of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in full upon the earlier of (i) June 20, 2024, and (ii) the 2024 annual meeting of the Issuer's stockholders, subject to continued service through such dates.

SEC source: 0000899243-23-010761 · doc4.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 14,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

F2 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0000899243-23-010761 · doc4.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

SEC source: 0000899243-23-010761 · doc4.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

SEC source: 0001562180-23-000098 · primarydocument.xml · derivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,124

Underlying: Common Stock · 12,124 shares

Expires 2033-01-03

F3 · shares: Represents non-qualified stock option to purchase 12,124 shares of common stock granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy.

SEC source: 0001562180-23-000098 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,291

F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2023 granted pursuant to the Quanterix Corporation Amended and Restated 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 11,110 restricted stock units.

SEC source: 0001593968-23-000078 · primary_01.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0001593968-23-000078 · primary_01.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

SEC source: 0001593968-23-000078 · primary_01.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001593968-22-001514 · primary_01.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0001593968-22-001514 · primary_01.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 8, 2022.

SEC source: 0001593968-22-001514 · primary_01.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001593968-22-001343 · primary_01.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,667

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0001593968-22-001343 · primary_01.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 6, 2021.

SEC source: 0001593968-22-001343 · primary_01.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001593968-22-001512 · primary_01.xml · derivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

F2 · balance_after: This Form 4/A amends the Form 4 filed by the reporting person on August 16, 2022 (the "Original Form 4"), which inadvertently reported the incorrect number of securities in column 9 of Table II. This Form 4/A is being filed solely to correct the number of securities reported in column 9 of Table II. No other amendments or changes have been made to the Original Form 4.

SEC source: 0001593968-22-001148 · primary_01.xml · derivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

Underlying: Common Stock · 5,000 shares

Expires 2032-06-14

F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 15, 2023, and (ii) the 2023 annual meeting of the Issuer's stockholders.

SEC source: 0001593968-22-001053 · primary_01.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0001593968-22-001053 · primary_01.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 6, 2021.

SEC source: 0001593968-22-001053 · primary_01.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001593968-22-000493 · primary_01.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0001593968-22-000493 · primary_01.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.

SEC source: 0001593968-22-000493 · primary_01.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-22-000224 · primarydocument.xml · derivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,002

Underlying: Common Stock · 4,002 shares

Expires 2032-01-03

F3 · shares: Represents non-qualified stock option to purchase 4,002 shares of common stock granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy.

SEC source: 0001562180-22-000224 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,208

F1 · shares: Represents restricted stock units that vest as to 100% of the shares on December 31, 2022 granted pursuant to the Quanterix Corporation 2018 Non-Employee Director Compensation Policy. Each restricted stock unit represents the right to receive one share of the Issuer's common stock.

F2 · balance_after: Includes 7,208 restricted stock units.

SEC source: 0001593968-21-002386 · primary_01.xml · derivative · entry 3

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 1,000 shares

Expires 2030-08-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: This option vests and becomes exercisable in thirty-six equal monthly installments beginning on August 12, 2020.

SEC source: 0001593968-21-002386 · primary_01.xml · nonDerivative · entry 2

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 15, 2021.

SEC source: 0001593968-21-002386 · primary_01.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001562180-21-004769 · primarydocument.xml · nonDerivative · entry 1

OLSON LAURIE J · CIK 0001553231 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,644

F1 · shares: Consists of stock granted in lieu of cash fees for service on the Company's Board of Directors and committees thereof for the second quarter of 2021.

F2 · price: Closing price of the Company's common stock on the Nasdaq Global Market on July 1, 2021.

F3 · balance_after: Includes 4,540 restricted stock units.